Abstract: This invention relates to enzymes, to rDNA techniques applicable for example to their production, to mutated genes, vectors and mutant and transformed microorganisms useful in their production, and to their uses including for example enzymatic detergent and cleaning compositions containing them.

Abstract: The invention employs GLP-1(7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.

Abstract: A dispenser for consecutive dispensing of tablets in a fixed order comprising a cylindrical body defining along its periphery a number of juxtaposed vertical chutes each accommodating a number of tablets piled on edge radially oriented in the body, a cup shaped dispensing part comprising a bottom plate having an upstanding cylindric wall and forming a stop at the lower end of the chutes. An opening in the cylindric wall allows a tablet on edge to pass from the outside of the cup into the inner space thereof. Above the opening a protrusion extends radially outwards from the cylindric wall into the space between a tablet abreast of the opening and a possible overlying tablet in the chute, and a wall adjacent to the opening extends into the lower ends of the chutes. A detent mechanism makes the body and dispensing part stepwise unidirectionally rotatable in relation to each other.

Abstract: A variant of the C-terminal Kunitz-type protease inhibitor domain of the .alpha.3 chain of human type VI collagen, the variant comprising the following amino acid sequence X.sup.1 X.sup.16 Asp Ile Cys Lys Leu Pro Lys Asp X.sup.2 Gly X.sup.3 Cys X.sup.4 X.sup.5 X.sup.6 X.sup.7 X.sup.8 X.sup.9 Trp Tyr Tyr Asp Pro Asn Thr Lys Ser Cys Ala Arg Phe X.sup.10 Tyr Gly Gly Cys X.sup.11 X.sup.12 X.sup.13 Glu Asn Lys Phe X.sup.14 Ser Gln Lys Glu Cys Glu Lys Val Cys Ala Pro X.sup.15 (SEQ ID NO. 1) wherein X.sup.1, X.sup.15, and X.sup.16 represents a naturally occurring amino acid residues except Cys and X.sup.2 -X.sup.14 each independently respresents a naturally occurring amino acid residue, with the proviso that at least one of the amino acid residues X.sup.1 -X.sup.16 is different from the corresponding amino acid residue of the native sequence. Alternatively, the N-terminal Asp may be preceded by H or 3-5 amino acid residues and the C-terminal Pro may be followed by OH or 3-5 amino acid residues.

Abstract: A pen shaped syringe for repetitive injection of individually set doses of a medicine from a cylinder ampoule reservoir comprises a dose setting member which may be rotated to cause a rotative movement of a dosing member and a combined rotative and axial movement of an indicator member indicating the set dose, and a piston drive member which when rotated in one direction moves the piston into the cylinder ampoule. A unidirectional coupling is established between the dosing member and the piston drive member by each member carrying a disc having surfaces with sector shaped saw teeth riding over each other when the dosing member is rotated in the dose setting direction and engaging each other when the dosing member is rotated in the opposite direction corresponding to the direction of rotation by which the piston is moved into the cylinder ampoule.

Abstract: The molecular characteristics and a partial amino acid sequence of an endo-.beta.-1,4-glucanase obtainable from Aspergillus aculeatus are described, as well as corresponding recombinant DNA sequences, vectors, and transformed hosts. Use of the endo-.beta.-1,4-glucanase or a pectinase preparation enriched with the endo-.beta.-1,4-glucanase for degradation or modification of plant cell walls is described.

Abstract: A process for the microbial production of a protein susceptible to inactivation in a fluid production medium by continuously and reversibly protecting said protein against said inactivation during the production stage, separating the protein from the production medium, deprotecting the protein, and recovering the protein product. The process is especially useful for obtaining substantially increased yields of the protein in question by continuously precipitating said protein.

Abstract: The invention is directed to an isolated nucleic acid construct(s) comprising a nucleic acid sequence encoding an alkaline protease having a molecular weight of about 34 kD and is obtainable from a strain of Bacillus sp. Group I, as well as recombinant vectors and host cells comprising such constructs. Additionally, the invention is directed to a method for obtaining the protease. The invention is also directed to promoter and signal sequences derived from said alkaline protease as well as methods of using the promoter and signal sequences in the expression of heterologous nucleic acid sequences encoding heterologous proteins in bacteria.

Abstract: The invention is directed to an isolated nucleic acid construct(s) comprising a nucleic acid sequence encoding an alkaline protease having a molecular weight of about 34 kD and is obtainable from a strain of Bacillus sp. Group I, as well as recombinant vectors and host cells comprising such constructs. Additionally, the invention is directed to a method for obtaining the protease. The invention is also directed to promoter and signal sequences derived from said alkaline protease as well as methods of using the promoter and signal sequences in the expression of heterologous nucleic acid sequences encoding heterologous proteins in bacteria.

Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.

Abstract: The invention is directed to an isolated nucleic acid construct(s) comprising a nucleic acid sequence encoding an alkaline protease having a molecular weight of about 34 kD and is obtainable from a strain of Bacillus sp. Group I, as well as recombinant vectors and host cells comprising such constructs. Additionally, the invention is directed to a method for obtaining the protease. The invention is also directed to promoter and signal sequences derived from said alkaline protease as well as methods of using the promoter and signal sequences in the expression of heterologous nucleic acid sequences encoding heterologous proteins in bacteria.

Abstract: A method of producing a fiberboard having improved mechanical properties such as water uptake (swelling), tensile strength perpendicular to the surface (IB), modulus of elasticity (MOE), and modulus of rupture (MOR) of the resulting fiberboard. The method includes providing a slurry of lignin-containing wood fiber material, adding a phenol oxidizing enzyme system, forming a mat of the wood fiber material, and pressing the formed mat by applying heat and pressure.

Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.

Abstract: The present invention relates to a human Kunitz-type protease inhibitor comprising the following amino acid sequenceAsp Leu Leu Pro Asn Val Cys Ala Phe Pro Met Glu Lys Gly Pro Cys Gln Thr Tyr Met Thr Arg Trp Phe Phe Asn Phe Glu Thr Gly Glu Cys Glu Leu Phe Ala Tyr Gly Gly Cys Gly Gly Asn Ser Asn Asn Phe Leu Arg Lys Glu Lys Cys Glu Lys Phe Cys Lys Phe Thr(SEQ ID NO:1)or a variant thereof with protease inhibitor properties.

Abstract: A process for hydrolysis of water-insoluble esters in the presence of a lipase, at a pH in the range of 3-7 particularly to such a process for hydrolysis of resin in pulp.

Abstract: This invention relates to lipase containing pharmaceutical compositions comprising a microbial, 1, 3-position specific, crystalline lipase and to methods for treatment or prophylaxis of lipase deficiency in mammals.

Abstract: A pen-shaped syringe comprises a first part containing a dose setting and driving mechanism from which a piston rod is advanced by a carrier to actuate a piston of a reservoir in a second part. The first and second parts are coupled together by a bayonet coupling, wherein the bayonet coupling element of the second part has members for rotating a piston rod guide mounted on the bayonet coupling element of the first part. The piston rod determines the rotational position of the piston rod which rotational position again determines the engagement between the carrier and the piston rod.

Abstract: The present invention relates to a novel method for treating a mammal suffering from urinary bladder dysfunctions.

Abstract: A coagulation active complex of Factor VIII fragments is produced by causing coagulation inactive FVIII heavy chain to react with coagulation inactive FVIII light chain in the presence of a complex forming agent. Thus, FVIII-HC and FVIII-LC are converted to coagulation active FVIII complex in the presence of divalent metal ions, such as Mn.sup.2+, Ca.sup.2+ or C.sup.2+, or a component of the pro-thrombin complex.

Abstract: The xylanase is characterized by several partial amino acid sequences and is immunoreactive with an antibody raised against a purified xylanase derived from Humicola insolens, DSM 1800. This xylanase preparation is practically free of cellulase xylanase and is well suited for treatment of paper pulp, as a baking agent and as an additive to fodder.